Janssen Pharmaceutica Nv

Andrew V Samant

Michael Anthony Letavic

Curt A Dvorak

Michael K Ameriks

Christine Fang Gelin

Brice M Stenne

Pablo Garcia-Reynaga

Cynthia B Berry

Christa C Chrovian

Afton Hiscox

Jesus Alcazar

Akinola Soyode-Johnson

J A Vega-Ramiro

Warren Stanfield Wade

Jessica L Wall

Brian Ngo Laforteza

Krisztián Biró

Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators

Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, m, n, o, and p are defined herein.

Azaspirocycles as monoacylglycerol lipase modulators

Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R,, R, and L are as defined herein.

Cyclobutyl amide monoacylglycerol lipase modulators

Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R, R, R, R, Rand Rare as defined herein.

Aryl piperidines as monoacylglycerol lipase modulators

Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators

Growing community of inventors

Cardiff, CA, United States of America

Andrew V Samant